4114 Stock Overview
Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches and develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand name in Taiwan.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Synmosa Biopharma Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$38.70 |
| 52 Week High | NT$46.12 |
| 52 Week Low | NT$34.90 |
| Beta | 0.28 |
| 1 Month Change | -0.77% |
| 3 Month Change | 3.48% |
| 1 Year Change | -6.43% |
| 3 Year Change | 100.44% |
| 5 Year Change | 116.86% |
| Change since IPO | 505.67% |
Recent News & Updates
Recent updates
Is Synmosa Biopharma Corporation (GTSM:4114) A Smart Pick For Income Investors?
Apr 04
If You Had Bought Synmosa Biopharma (GTSM:4114) Stock Three Years Ago, You Could Pocket A 22% Gain Today
Mar 08Should Weakness in Synmosa Biopharma Corporation's (GTSM:4114) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Jan 31Is Synmosa Biopharma (GTSM:4114) A Risky Investment?
Jan 05Here's Why We Don't Think Synmosa Biopharma's (GTSM:4114) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 09
Shareholder Returns
| 4114 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -1.0% | -5.4% | -2.1% |
| 1Y | -6.4% | 3.0% | 27.5% |
Return vs Industry: 4114 underperformed the TW Pharmaceuticals industry which returned 3% over the past year.
Return vs Market: 4114 underperformed the TW Market which returned 27.5% over the past year.
Price Volatility
| 4114 volatility | |
|---|---|
| 4114 Average Weekly Movement | 2.4% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 8.3% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4114 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4114's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | n/a | Chih-Hui Lin | www.synmosa.com.tw |
Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches and develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand name in Taiwan. It offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company provides its products in various forms, such as effervescent tablets, granules, nasal sprays, metered dosed inhalers, hormones, and other forms.
Synmosa Biopharma Corporation Fundamentals Summary
| 4114 fundamental statistics | |
|---|---|
| Market cap | NT$14.79b |
| Earnings (TTM) | NT$594.83m |
| Revenue (TTM) | NT$5.14b |
24.9x
P/E Ratio2.9x
P/S RatioIs 4114 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4114 income statement (TTM) | |
|---|---|
| Revenue | NT$5.14b |
| Cost of Revenue | NT$3.02b |
| Gross Profit | NT$2.12b |
| Other Expenses | NT$1.53b |
| Earnings | NT$594.83m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.56 |
| Gross Margin | 41.24% |
| Net Profit Margin | 11.57% |
| Debt/Equity Ratio | 29.0% |
How did 4114 perform over the long term?
See historical performance and comparison